Literature DB >> 3967166

Dosimetry of cytostatics in hyperthermic regional isolated perfusion.

J van Os, H Schraffordt Koops, J Oldhoff.   

Abstract

During the period from February to October 1983, 21 patients with malignant melanoma of the extremities were treated by hyperthermic regional isolated perfusion with L-phenylalanine mustard (melphalan). The melphalan dose for each patient was determined by the tissue volume of the perfused region, using a dose of 10 mg/l perfused tissue. Despite an average increase of melphalan dosage of 18% above the maximum for iliac perfusions recommended in the literature, no increase in toxic tissue reactions was observed after hyperthermic iliac perfusions. The same dose of 10 mg/l perfused tissue was used in hyperthermic axillary perfusions, resulting in an average decrease of melphalan dosage of 14% below the minimum recommended in the literature. By applying a constant dose per unit tissue volume, a standardization of treatment is achieved. This excludes variations like body weight, age, type of complexion, and hair color, which so far have determined dosimetry.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967166     DOI: 10.1002/1097-0142(19850215)55:4<698::aid-cncr2820550404>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Leakage measurement during selective limb perfusion using a gamma probe.

Authors:  D Sandrock; F Horst; W Gatzemeier; M Ghorbani; H Rauschecker; D L Munz; D Emrich
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Isolated regional perfusion in malignant melanoma of the extremities.

Authors:  H Schraffordt Koops; J Oldhoff; J W Oosterhuis; H Beekhuis
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

3.  Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.

Authors:  H Schraffordt Koops; B B Kroon; J Oldhoff; H J Hoekstra
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

5.  Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

Authors:  H J Guchelaar; H J Hoekstra; E G de Vries; D R Uges; J W Oosterhuis; H Schraffordt Koops
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

6.  Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation.

Authors:  Lars Erik Podleska; Thorsten Poeppel; Michael Herbrik; Lisa Dahlkamp; Florian Grabellus; Georg Taeger
Journal:  World J Surg Oncol       Date:  2014-04-01       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.